Kyorin Pharmaceutical
As of the edition of 20 October 2026, Kyorin Pharmaceutical runs 11 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 9 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Formoterol | none listed | 2 |
| Fluticasone propionate | none listed | 2 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Fluticasone | none listed | 2 |
| Aclidinium | none listed | 2 |
| Ibudilast | none listed | 6 |
| Vibegron | Ends 2034 (patent) | 2 |
| Dimethyl sulfoxide | none listed | 0 |
| Imidafenacin | none listed | 2 |
| Lascufloxacin | none listed | 0 |
| Simetride | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 9 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where Kyorin Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.